about
Multiple human vault RNAs. Expression and association with the vault complexMicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmationThe vault complexIncreased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault proteinPractical aspects of managing gastrointestinal stromal tumors.Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.Renal function as a predictor of irinotecan-induced neutropenia.Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated areaThe applicability of mTOR inhibition in solid tumors.Effects of methimazole on the elimination of irinotecan.Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.MicroRNAs in ovarian cancer biology and therapy resistance.Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.Evaluation of patient enrollment in oncology phase I clinical trials.Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3αCircadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cellsVisualization of the peroxisomal compartment in living mammalian cells: dynamic behavior and association with microtubules.miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity.Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in miceThe role of microRNAs in cancer: no small matter.miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumoursExpression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.Loss of SLCO1B3 drives taxane resistance in prostate cancerCross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy.Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.The formation of vault-tubes: a dynamic interaction between vaults and vault PARP.Inducible Major Vault Protein Plays a Pivotal Role in Double-Stranded RNA- or Virus-Induced Proinflammatory Response.Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.
P50
Q24291500-3B6C47C1-4FA1-42AC-9F61-F7B33627A727Q24594126-6B64EAB9-8E37-4EF2-B5FF-3C3782DEAC72Q28206644-8154B941-AA7B-4448-9294-9E8AF19A0CFAQ28216376-034A54D2-F267-4260-A936-F98E9ECBDB85Q30832090-6D21C9BA-DAD7-4644-8B21-12380F9D52F5Q33263451-797D61DC-CD92-4956-B513-767688D25DB4Q33289378-45C589BD-74EB-42DF-9546-8AE2DCCBEED6Q33297437-0C648BCB-B3B1-4E72-98FC-B6DBC6CBD4BEQ33320638-AA3843A2-9FD8-47E7-A168-38F2DB3CEA43Q33391666-A1A07D4A-14E0-424A-9F83-496454DF1BD2Q33420218-85EF7C60-5A10-4C22-AC89-7FBBB263330DQ33445767-E03E019D-17F6-40A6-A2BC-90540B3135F7Q33647853-8EB20952-999B-4ACA-9012-7929845A86A7Q33788732-C332BB3F-6CA9-471A-8B75-FB8435ADC984Q34093466-9DB275E0-A030-402F-AA99-4D86118B13D7Q34556770-C934F661-4067-4F4C-B6B7-0A1A6E689B0BQ34594562-83BBAD44-EDC2-453D-8A1F-9352DFBB973AQ34975423-556D9A40-9889-4348-A38F-DE398BB3E641Q35187892-4A83A72B-CDB7-4A82-9A49-11116330B0CFQ35747766-64F1CD82-D066-4FB3-8B7E-92FC0A37C741Q35884179-C0497ED0-6C6A-4A99-9CA8-69AB0D86B044Q35924139-4CE165D1-FF54-4826-AF90-02A8B8DFCAACQ36254473-B9D83209-CCDB-4843-A668-2539F33989A9Q36293209-88511C0D-119B-4DE3-BE82-72388D4975F4Q36387641-E488CDBA-7C2C-491B-8BD2-03C0EF6923E4Q36599618-8DBD9090-B090-4D68-8E33-86564FEE3768Q36832677-5F387B16-F1EB-4357-A10F-F70970628A60Q36902949-126EAD8C-2440-4990-B717-18ACFD09DBEEQ36940993-FA9B297D-5A5A-41F7-89D7-FB12C5CA3C49Q37182248-7505290A-7E6A-43AA-A5D8-DAE14D2A121FQ38694793-868A1893-5206-4981-B5F3-C143FDCC6CE6Q38751260-7C507A93-B632-4B8D-9EFF-A62FE3583A10Q39066256-4429D2BF-CAEB-430B-AB23-73C1D9A21178Q39265086-DE6E3EC3-119A-4DA3-B8DE-6CA9DB8BB14EQ40144080-DC021B57-49C2-4A1E-83FC-1F89E60828A8Q40548720-1126A803-2B75-4D6C-9DCE-EF7C38670DBCQ40634187-520DBA05-C00A-444B-9817-7D2BE22AA4C3Q40806217-FCF746BF-2A24-44E2-A121-68FDC699CF12Q40933473-0D58C708-ED05-4380-AA35-CB522A99289DQ41560943-50C819FF-012F-4C2B-90A5-7E5EFD7005C3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Erik Wiemer
@ast
Erik Wiemer
@en
Erik Wiemer
@es
Erik Wiemer
@sl
type
label
Erik Wiemer
@ast
Erik Wiemer
@en
Erik Wiemer
@es
Erik Wiemer
@sl
prefLabel
Erik Wiemer
@ast
Erik Wiemer
@en
Erik Wiemer
@es
Erik Wiemer
@sl
P106
P108
P1153
7003350150
P21
P31
P496
0000-0002-0673-7236